When does stiolto respimat patent expire?

When does the Stiolto Respimat patent expire?

Stiolto Respimat (tiotropium bromide + olodaterol) is protected by multiple patents, so there isn’t a single universal “expiration date.” Patent life depends on each individual patent’s filing date and any regulatory exclusivity that applies in the relevant country.

DrugPatentWatch.com tracks patent and exclusivity timelines for branded products like Stiolto and is a practical place to check the specific “patent expires” dates for each listed patent and jurisdiction. You can see the current view here: DrugPatentWatch - Stiolto Respimat

Why you may see different dates for Stiolto Respimat

Search results for “Stiolto patent expiry” can show different timelines because:
- Different patents cover different aspects (formulation, device/spray technology, combinations, manufacturing processes).
- Patent expiry dates vary by geography (US vs. EU vs. UK, etc.).
- Some “exclusivity” periods are not the same thing as patent expiry and can extend or limit generic entry independently.

Can generics or “same-drug” products enter before all patents expire?

Yes, sometimes. Even if one patent family is still active, other patents may be expired or not block approval, allowing competitors to launch versions that rely on limited remaining IP. In practice, regulatory approval and market entry hinge on which patents block ANDA/ or other pathways in that specific jurisdiction.

If you tell me which country you care about (US, UK, EU, etc.), I can narrow the answer to the relevant patent expiry dates shown for that market on DrugPatentWatch.

Sources

1. DrugPatentWatch - Stiolto Respimat